Price$3.56-0.14 (-3.81%)
2026-07-162026-10-16
News · 26 weeks39-8%
2026-04-192026-10-11
Mix2890d
- SEC Filings16(57%)
- Other8(29%)
- Insider2(7%)
- Leadership1(4%)
- Offering1(4%)
Latest news
25 items- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENTTransaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing DevelopmentREHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary share and accompanying warrants (or $3.7399
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRLightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering SimulationsCollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP PortfolioREHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced that its subsidiary, LightSolver, has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for an invention that significantly expands the capabilities of its all-optical, laser-based computing platform.The provisional application, titled "Configuring a Programmable Analog Processor to Solve Inhomogeneous Boundary Value Problems," details a proprietary method for solving a broad class of complex physical and engineering problems. The invention broadens the ran
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEStrategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative MedicineREHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.Yehiel Tal, CollPlant's Chief Executive Officer, commented: "The acquisition of LightSolver marks CollPlant's strategic entry into high-performance computing (HPC) and photonics computing markets, alongside our regenerative medicine activities. LightSolver's pioneering LPU technology, recently validated in a peer-reviewed study with Germany's HLRS dem
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRLightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC WorkloadsPeer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPUREHOVOT, Israel, September 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced the publication of joint research conducted by its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU), and the High-Performance Computing Center Stuttgart (HLRS), one of Europe's premier supercomputing institutions. Published in the proceedings of the 23rd
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCollPlant Regains Compliance with Nasdaq Minimum Bid Price RequirementNasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matterFollows the recent completion of the LightSolver acquisition, marking CollPlant's strategic expansion into high-performance computing (HPC) and photonicsREHOVOT, Israel, Sept. 22, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN), today announced the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's common stock to maintain a minimum bid price of $1.00 per share.
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCollPlant to Host LightSolver Investor Webinar on September 17, 2026REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced that its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing with the world's first Laser Processing Unit™ (LPU™), a fundamentally new computing architecture that uses light itself to compute, will host an investor webinar on Thursday, September 17, 2026, at 8:30 a.m. Eastern Time. During the webinar, LightSolver management will provide an introduction to the company and its technology, including its full-stack photonic computing architecture, the computational challenges and applications it
- INSIDERVP Legal Abelis Bar Berta was granted 201,141 units of Ordinary Shares, increasing direct ownership by 3,795% to 206,441 units (SEC Form 4)4 - CollPlant Biotechnologies Ltd (0001631487) (Issuer)
- INSIDERDeputy CEO and CFO Rotem Eran was granted 510,372 units of Ordinary Shares, increasing direct ownership by 8,506% to 516,372 units (SEC Form 4)4 - CollPlant Biotechnologies Ltd (0001631487) (Issuer)
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITIONLightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technologyREHOVOT, Israel, Sept. 4, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced the appointment of Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolver Ltd. ("LightSolver"), to CollPlant's Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver, as announced on September 3, 2026. LightSolver is pioneering a new generation of high p
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTORTechnological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platformAccelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand engagements with strategic partners.REHOVOT, Israel, Sept. 3, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced the successful closing of its previously announced acquisition of LightSolver Ltd. ("LightSolver"), an Israeli deep-tech company pioneering a fundamentally new computing paradigm based on lasers. With the
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT ANNOUNCES REVERSE SHARE SPLITREHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) ("CollPlant" or the "Company"), today announced that its Board of Directors has approved a one-for-ten reverse share split of the Company's ordinary shares. The reverse share split is scheduled to take effect when the Nasdaq Capital Market opens on September 4, 2026, at which point the Company's ordinary shares will begin trading on a split-adjusted basis under the existing ticker symbol "CLGN". The Board's decision follows shareholder approval granted at the Extraordinary General Meeting of Shareholders held on August 18, 2026. The reverse split is being implemented as part of the Company's strategic
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- PRCOLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETSLightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computingLightSolver has developed the world's first Laser Processing Unit™ (LPU™), combining the advantages of classical and quantum computing in a compact platform that operates without cryogenic or other extreme conditions and is designed for commercial deployment.Commercial validation is underway with global leaders across mission-critical industries, including Boeing, a top-tier global financial institution, leading defense companies, oil and gas and energy companies, and leading engineering software organ
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
- SECSEC Form 6-K filed by CollPlant Biotechnologies Ltd6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
CLGN FAQ
6 questionsWhat does CollPlant Biotechnologies Ltd do?
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue...Where does CLGN stock trade?
CollPlant Biotechnologies Ltd (CLGN) is listed on NASDAQ.What sector and industry is CLGN in?
CollPlant Biotechnologies Ltd operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about CLGN?
CollPlant Biotechnologies Ltd has had 1 recent analyst action on file. The most recent action was from Alliance Global Partners: Buy with a $2275.00 price target on 2023-02-17. Recent price targets cluster around $2275.00.What companies are similar to CLGN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare CLGN side-by-side with any of them on Quantisnow.How can I track CLGN on Quantisnow?
Quantisnow aggregates CollPlant Biotechnologies Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLGN to receive live email and push alerts on every new disclosure.